TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients

Hemodialysis International

Volumn 18, Issue 1, 2014, Pages 38-46

  Gaweda, Adam E ^a   Bhat, Premila ^b   Maglinte, Gregory A ^c   Chang, Chun Lan ^d   Hill, Jerrold ^d   Park, Grace S ^c   Ashfaq, Akhtar ^c   Gitlin, Matthew ^c  

^a University of Louisville School of Medicine   (United States)

^b Atlantic Dialysis Management Services   (United States)

^c AMGEN INC   (United States)

^d IQVIA   (United States)

Author keywords

Anemia; End stage renal disease; Erythropoiesis stimulating agent; Hemoglobin; Iron

Indexed keywords

FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AFRICAN AMERICAN; AGED; ANALYTICAL PARAMETERS; ARTICLE; CAUCASIAN; CHEMICAL MODIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TRANSFERRIN SATURATION; UNITED STATES; YOUNG ADULT;

ANEMIA; END-STAGE RENAL DISEASE; ERYTHROPOIESIS-STIMULATING AGENT; HEMOGLOBIN; IRON;

DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RENAL DIALYSIS; UNITED STATES;

EID: 84891903437     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12078     Document Type: Article

References (22)

1. ® (Epoetin Alfa) Package Insert. Thousand Oaks, CA: Amgen Inc.; 2012.
2. ® (Darbepoetin Alfa) Package Insert. Thousand Oaks, CA: Amgen Inc.; 2012.
3. Locatelli F, Nissenson AR, Barrett BJ, etal. Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008; 74:1237-1240.
4. NKF. National Kidney Foundation Dialysis Outcomes Quality Initiative: Clinical practice guidelines: Anemia of chronic renal failure. Am J Kidney Dis. 2001; 37:S182-S238.
5. Kalantar-Zadeh K, Don BR, Rodriguez RA, etal. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001; 37:564-572.
6. Kalantar-Zadeh K, Lee GH, Miller JE, etal. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009; 53:823-834.
7. Kalantar-Zadeh K, McAllister CJ, Lehn RS, etal. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis. 2004; 43:671-684.
8. Kalantar-Zadeh K, Regidor DL, McAllister CJ, etal. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16:3070-3080.
9. Besarab A, Amin N, Ahsan M, etal. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000; 11:530-538.
10. Coyne DW, Kapoian T, Suki W, etal. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol. 2007; 18:975-984.
11. Gaweda AE, Goldsmith LJ, Brier ME, etal. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol. 2010; 5:576-581.
12. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: A generalized estimating equation approach. Biometrics. 1988; 44:1049-1060.
13. Cui J. QIC program and model selection in GEE analyses. Stata J. 2007; 7:209-220.
14. Tsagalis G. Renal anemia: A nephrologist's view. Hippokratia. 2011; 15:39-43.
15. Bross R, Zitterkoph J, Pithia J, etal. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009; 29:571-581.
16. Kalantar-Zadeh K, McAllister CJ, Lehn RS, etal. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003; 42:761-773.
17. Robinson B, Fuller D, Zinsser D, etal. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: Rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011; 57:822-831.
18. DOPPS Practice Monitor. Available from: http://www.dopps.org (accessed date: February 21, 2013.
19. Hoen B, Paul-Dauphin A, Hestin D, etal. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998; 9:869-876.
20. Drueke T, Witko-Sarsat V, Massy Z, etal. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212-2217.
21. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012; 69:310-320.
22. Rostoker G, Griuncelli M, Loridon C, etal. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study. Am J Med. 2012; 125:991.e1-999.e1.